

# May 6, 2022 | Issue 220

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare Regulatory</u> <u>Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply here to</u> <u>me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here

### Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have <u>summarized COVID-19 news for the week</u> in a special supplement.

0



CMS <u>finalized 2023 Medicare Advantage and Part D policies</u>, including requiring Part D plans <u>apply all pharmacy price concessions at the point of sale</u> beginning in 2024.

HHS <u>reported enrollment</u> for Medicaid expansion, marketplace coverage, and the Basic Health Program has reached <u>an all-time high (35M+)</u>... CMS <u>approved</u> <u>Michigan's plan</u> to expand Medicaid coverage to new mothers up to a year postpartum... HHS <u>suspended Georgia's plan</u> to block residents from <u>using healthcare.gov for ACA plan enrollment</u> and instead require using insurers/brokers.

FDA approved the first in vitro Alzheimer's diagnostic test and expanded approval of a non-stimulant ADHD drug to include adults.

HRSA projected primary care physician shortages in 37 states by 2025... HRSA awarded \$25M to expand access to school-based health services.

0



Healthcare law and policy news

A leaked Supreme Court draft majority opinion would strike down Roe v. Wade.

Washington <u>reached a \$518M settlement with three pharmaceutical wholesalers</u> over opioid-related claims... Walgreens will <u>pay Florida \$683M to settle</u> opioid-related claims... Department of Justice <u>charged 12 medical professionals</u> with unlawful opioid distribution.

UnitedHealthcare will <u>restrict coverage of Aduhelm</u> beginning <u>June 1</u>... Biogen <u>will</u> <u>replace its CEO</u> and <u>effectively eliminate marketing</u> for Aduhelm... Cerebral will <u>stop prescribing controlled substances for ADHD</u> amid a DEA investigation... PillPack will <u>pay the federal government and states \$5.79M</u> to settle insulin overbilling allegations.

KPMG, EBG, and FocalPoint reported Q1 healthcare and life sciences <u>deal</u> <u>volume is down over 10%</u> from Q1 2021... Centene will <u>sell Magellan Rx and</u> <u>PANTHERx Rare</u> (\$2.8B).

A <u>CMS-RAND study</u> found Black, American Indian/Alaska Native, and Hispanic Medicare Advantage enrollees experienced significant disparities in 2021 clinical care... American Academy of Pediatrics <u>recommended eliminating</u> race-based <u>medical guidelines</u>.

House Energy & Commerce Committee <u>leaders released legislation</u> to <u>reauthorize</u> <u>FDA user fees</u>, which includes <u>Accelerated Approval Program reforms</u>... House Republicans <u>released a one-page plan</u> to lower prescription drug costs and accelerate drug approval/access.

*Health Affairs* studies found 1) people in the <u>most disadvantaged neighborhoods</u> were more likely to use telemedicine following the March 2020 Medicare coverage waiver; 2) just <u>6% of FDA-approved drugs were referred to an advisory committee</u> <u>in 2021</u>, down from 55% in 2010... Kaufman Hall reported April <u>hospital outpatient</u> <u>revenue was up 16.1%</u> compared to February.

0



Questions or comments, please send to <u>us-hcinsight@kpmg.com</u>.

kpmg.com/socialmedia



Privacy | Legal

This email was sent by KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



# COVID-19 News Supplement

**Center for Healthcare Policy Insight** 



## COVID-19 by the Numbers

Approximately <u>81.6 million COVID-19 cases</u> have been documented in the US, with a death toll of over 995,000 (NBC News data suggests the <u>death toll now exceeds 1 million</u>)... The country <u>averaged over</u> <u>60,000 cases/day</u> over the past week, up from approximately 40,000/day two weeks ago, with cases rising in all but four states and Washington, DC; meanwhile, COVID-related deaths averaged <u>over</u> <u>300/day</u> over the past week, down from approximately 350/day two weeks ago... World Health Organization estimates <u>excess mortality associated with COVID-19 was 14.9 million</u> between January 1, 2020 and December 31, 2021; meanwhile, <u>global cases and deaths were down 17% and 3%</u>, respectively, over the past week.

The BA.2 variant accounts for <u>approximately 62% of COVID-19 cases</u> in the US, while a sub-lineage, BA.2.12.1, accounts for 37% of cases.

More than <u>11.6 billion COVID-19 vaccine doses have been administered across 184 countries</u>... Over 576 million COVID-19 <u>vaccine doses have been administered</u> in the US... Over 257 million Americans (<u>approximately 82.5% of Americans 5 and older</u>) have received at least one COVID-19 vaccine dose; nearly 220 million Americans are fully vaccinated (70.4% of Americans 5 and older); over 100 million Americans have received a booster or additional dose (just 45.9% of those fully vaccinated).

# Executive and Administrative Action

CDC's travel mask mandate would have ended or been extended on Tuesday had a district judge last month not put a nationwide injunction on the requirement; however, CDC <u>issued a recommendation</u> that everyone ages 2 and older continue wearing masks on planes, buses, trains, and other forms of public transportation.

# Healthcare Law, Business, and Policy News

Based on low test sensitivity after initial infection, <u>authors of a JAMA study</u> suggest repeating negative home antigen tests for COVID-19 one to two days after illness onset.

Senator Rand Paul (R-KY) said Republicans <u>would investigate the origins of COVID-19 if the party wins</u> the Senate majority and he were to become chair of a committee.

Bill Gates called for a global task force and more funding to prevent future pandemics.

A <u>JAMA study found deaths related to alcohol use disorder</u> increased 25% in 2020 and 22% in 2021, driven by increased consumption during the pandemic.

A <u>KFF survey found 18% of parents</u> with children under age 5 plan to get their child vaccinated for COVID-19 "right away" once authorized, while 38% plan to "wait and see," and 11% "only if required." 88% of workers say they feel "very safe" (55%) or "somewhat safe" (33%) from COVID-19 in the workplace; however, Black (31%), Hispanic (48%), and lower-income workers (41%) are less likely to feel "very safe"... A Littler Mendelson survey found <u>41% of employers have some type of COVID-19 vaccine mandate in place</u> for employees.

### Surveillance, Testing, and Treatment

FDA's vaccine advisory committee <u>plans to meet</u> June 8 and June 21-22 to discuss possible authorization of Pfizer-BioNTech's and Moderna's COVID-19 vaccines in younger populations, June 7 to consider emergency authorization for Novavax's COVID-19 vaccine, and June 28 to discuss whether to modify the composition of COVID-19 vaccines to account for newer strains.

Due to the risk of rare blood clots, FDA <u>limited use of Johnson & Johnson's COVID-19 vaccine</u> to individuals 18 and older for whom other COVID-19 vaccines are not accessible or clinically appropriate and individuals who refuse to get a different COVID-19 vaccine.

FDA leaders wrote in *JAMA* that <u>annual COVID-19 vaccines</u>, with strain composition updates, will likely be needed.

Pfizer <u>plans to submit data to the FDA on its three-dose pediatric COVID-19 vaccine</u> for children 6 months to 4 years "in the next few weeks."

Moderna has signed <u>contracts worth \$21 billion for its COVID-19 vaccines</u> with buyers around the world through the rest of the year, but none with the US government.

Pfizer reported its <u>COVID-19 antiviral pill</u>, <u>Paxlovid</u>, is not effective for post-exposure prophylaxis (i.e., preventing infection)</u> in those living in the same household as someone who has COVID-19... FDA issued <u>a checklist</u>, <u>FAQ guidance document</u>, and updated <u>fact sheet</u> for healthcare providers who prescribe Paxlovid... NIH is planning studies to understand <u>why COVID-19 comes back in some COVID-19 patients</u> who have completed a five-day course of Paxlovid, while Pfizer's CEO said patients who show relapse in COVID-19 symptoms after taking a full course of the treatment <u>should take more</u> (despite <u>FDA EUA</u> guidelines and <u>agency statements</u> contradicting the advice).

White House COVID-19 budget documents provided to Congress suggest that if the Administration encourages all adults to get a second COVID-19 booster dose, <u>the supply of vaccine doses could run out</u> by <u>September 1</u>. Additional funding will be needed to procure at least 87 million more vaccines for adult boosters and 5 million more for first boosters for children.

Bureau of Prisons records show that <u>federal prisons have used just a fraction of antiviral COVID-19</u> <u>treatments</u> allocated to them to prevent serious illness or death in incarcerated individuals.